# A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

> **NCT04586426** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 228 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Talquetamab
- **DRUG:** Teclistamab

## Key facts

- **NCT ID:** NCT04586426
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-15
- **Primary completion:** 2025-03-18
- **Final completion:** 2026-10-27
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04586426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04586426, "A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04586426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*